Biotech Values

[DewDiligence]

IDIX 2009 Clinical Goals

[Updated for 4Q08 CC.]


HCV

April 2009: Possibly report partial results of IDX184 monotherapy study at EASL. (This depends on whether there are enough patients treated by the abstract deadline.)

Mid 2009: Complete IDX184 monotherapy study.

Mid 2009: Start IDX184 phase-2a combination study (SoC ± IDX184).

Mid 2009: File IND for IDX375 non-nucleoside polymerase inhibitor.

Late 2009: File IND for IDX136 and IDX316 protease inhibitors.


HIV

Any time after H-S-R clearance of GSK partnership: Start IDX899 phase-2 head-to-head trial vs Sustiva.